Letter to the Editor
Comment on Medicine Access Programmes: what do patients think – a patient-reported outcome study on ribociclib in metastatic breast cancer in Australia
Anita Shutt,
Anita Shutt
Council of Australian Therapeutic Advisory Groups, Sydney, New South Wales, Australia
Search for more papers by this author Lisa Pulver,
Lisa Pulver
Council of Australian Therapeutic Advisory Groups, Sydney, New South Wales, Australia
Search for more papers by this author Julie Briggs,
Julie Briggs
Council of Australian Therapeutic Advisory Groups, Sydney, New South Wales, Australia
Search for more papers by this author
Anita Shutt,
Anita Shutt
Council of Australian Therapeutic Advisory Groups, Sydney, New South Wales, Australia
Search for more papers by this author Lisa Pulver,
Lisa Pulver
Council of Australian Therapeutic Advisory Groups, Sydney, New South Wales, Australia
Search for more papers by this author Julie Briggs,
Julie Briggs
Council of Australian Therapeutic Advisory Groups, Sydney, New South Wales, Australia
Search for more papers by this author
First published: 26 June 2025
No abstract is available for this article.
References
- 1Yap N, Wong V, Morton C, De Boer R, Baron-Hay S, Blum R et al. Medicine Access Programmes: what do patients think – a patient-reported outcome study on ribociclib in metastatic breast cancer in Australia. Intern Med J 2024; 54: 1894–1897.
- 2 Council of Australian Therapeutic Advisory Groups. Managing Medicines Access Programs. Guiding principles for the governance of Medicines Access Programs in Australian hospitals. CATAG; 2018 (18 December 2024). Available from: https://catag.org.au/resource/managing-medicines-access-programs/.
- 3 Council of Australian Therapeutic Advisory Groups. Understanding medicines access programs. CATAG; 2024 (18 December 2024). Available from: https://catag.org.au/resource/consumer-resource-map/.
